The DOI matches its Crossref record.
Vaccine Adjuvants
Abstract
Nonreplicating, purified subunit or synthetic viral vaccines of the future are likely to be weak immunogens that will require immunopotentiation if they are to be effective. These marginal vaccines could be improved by combination with potent and safe immunologic adjuvants. The use of adjuvants should also reduce the amount of purified antigen required for successful immunization, thus making vaccine production more economical and more feasible. It may be possible to combine the recently developed relatively nontoxic synthetic immunoregulators of low molecular weight with antigens in order to modulate preselected compartments of the immune system. To date, the question of adjuvant safety has not been resolved and represents the major obstacle to the orderly development of adjuvanted vaccines. The fear of inducing cancer and other immediate or long-term perturbations of the immune system must be patently and rationally overcome by basic and applied experimentation and by the development of appropriate guidelines for studies in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Adjuvants for human vaccines—current status, problems and future prospects
Gupta, R. K., & Siber, G. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00011-o · Cited by 551
Adjuvants — a balance between toxicity and adjuvanticity
Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., & Gupta, C. K. (1993) · Vaccine · doi:10.1016/0264-410x(93)90190-9 · Cited by 545
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Aluminium compounds for use in vaccines
Lindblad, E. B. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01286.x · Cited by 488
Metabolism and possible health effects of aluminum.
Ganrot, P. O. (1986) · Environmental Health Perspectives · doi:10.1289/ehp.8665363 · Cited by 483
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Adjuvants designed for veterinary and human vaccines
Aucouturier, J., Dupuis, L., & Ganne, V. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00498-9 · Cited by 430
Aluminum salts in vaccines—US perspective
Baylor, N. W., Egan, W., & Richman, P. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00166-4 · Cited by 369
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Liposomes as carriers of antigens and adjuvants
Alving, C. R. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90120-5 · Cited by 344
Adjuvant Properties of Aluminum and Calcium Compounds
Gupta, R. K., Rost, B. E., Relyveld, E., & Siber, G. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_8 · Cited by 330
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
O’Hagan, D. T. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.699 · Cited by 282
The path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
Metadata
- Authors
- Edelman, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1980-05-01
- Volume
- 2
- Issue
- 3
- Pages
- 370-383
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4244506835
- Cited by
- 245
- References
- 0
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.